Antiviral treatment and statin use and risk of decompensated cirrhosis in patients with hepatitis C: a time-dependent analysis of a retrospective cohort study - Summary - MDSpire
Conexiant’s news site is now MDSpire News. Learn more
Advertisement
Evaluating the Impact of Antiviral Therapy and Statin Administration on the Risk of Decompensated Cirrhosis in Hepatitis C Patients: A Time-Dependent Retrospective Cohort Study
To evaluate the interplay between antiviral treatment and statin use and the risk of decompensated cirrhosis (DC) among patients with HCV over time.
Approach:
Study Design: Retrospective cohort study using data from the Chronic Hepatitis Cohort Study, analyzing time-varying antiviral treatment and statin use.
Data Collection: Data collected from 16,275 patients with HCV from 2006 to 2018, focusing on treatment status and outcomes related to DC.
Statistical Analysis: Used propensity score weighting and a pseudo-observation approach to assess the risk of DC over time.
Key Findings:
Sustained virological response (SVR) was associated with a reduced risk of DC (adjusted HR 0.17).
Statin use was linked to a lower risk of decompensation (adjusted HR 0.68).
The proportion of patients without antiviral treatment decreased from 36% to 11% over 15 years, while statin use increased from 12% to 28%.
Interpretation:
Limitations:
The study is observational and may be subject to residual confounding.
Findings may not be generalizable to populations outside the study cohort.
